Articles by Shambavi Richard, MD
The panel advises on patient hand off to local care teams following CAR T-cell therapy for myeloma.
The panel discusses side effect management with CAR T-cell therapy.
The panel addresses the choice between treating multiple myeloma with a bispecific agent or CAR T-cell therapy.
Drs. Martin and Voorhees discuss patient characteristics and populations that are suited for CAR-T therapy in myeloma.
The panel addresses the potential for frontline CAR-T use.
The panel debates whether CAR-T can be moved earlier in the course of myeloma treatment.
The panel discusses allogeneic CAR T-cell therapy and how it stacks up against autologous options.
Drs. Lonial and Martin discuss allogeneic, off-the-shelf CAR-T data.
BCMA-targeted autologous CAR T-cell therapies are discussed.
The panel discusses the second FDA-approved CAR-T therapy for myeloma, ciltacabtagene autoleucel.
Drs. Voorhees and Martin discuss one of the FDA-approved CAR-T therapies for myeloma, idecabtagene vicleucel.
In the first segment of the roundtable series, the panel discusses BCMA as an important target for treating multiple myeloma.
Dr. Richard hopes that one day she can confidently tell patients facing a multiple myeloma diagnosis that there is a cure.
Shambavi Richard, discusses a retrospective study on extramedullary disease and CAR-T in multiple myeloma.
670 Madison Ave.
Manalapan, NJ 07726